Concepedia

David R. Spriggs

DR

Statistics

Publications

169

Citations

16.6K

H-Index

71

Active since

1984

Affiliations

Memorial Sloan Kettering Cancer Center(Current)

Dana-Farber Cancer Institute

Harvard University

Cornell University

The University of Texas MD Anderson Cancer Center

David R. Spriggs is an author at Memorial Sloan Kettering Cancer Center specializing in oncology, medicine, and chemotherapy.

ORCID

Publications per year

1984–2024

169

Publications

169

Detection of Circulating Tumor Necrosis Factor after Endotoxin Administration

H. R. Michie, Kirk R. Manogue, David R. Spriggs et al. · New England Journal of Medicine · 1988 · 1.7K citations

, , +11

Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II Trial

Martee L. Hensley, Robert G. Maki, Ennapadam Venkatraman et al. · Journal of Clinical Oncology · 2002 · 688 citations

, , +14

Increased tumor necrosis factor alpha mRNA after cellular exposure to ionizing radiation.

Dennis E. Hallahan, David R. Spriggs, Michael A. Beckett et al. · Proceedings of the National Academy of Sciences · 1989 · 467 citations · Full text

, , +15

A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.

Carol Aghajanian, Steven L. Soignet, Don S. Dizon et al. · PubMed · 2002 · 456 citations

, , +14

IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors <i>in vivo</i>

Mythili Koneru, Terence J. Purdon, David R. Spriggs et al. · OncoImmunology · 2015 · 414 citations · Full text

, , +17

1–5 of 169